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Pittsburgh Sleep Quality Index
Sleep quality
a  b  s  t  r  a  c  t
Introduction: Ankylosing spondylitis (AS) is a chronic, inﬂammatory rheumatic disease char-
acterized by the inﬂammation of the pelvis and spine that results in a restriction in the
mobility of the spine. Due to the altered posture and nocturnal inﬂammatory pain, sleep
disturbances are likely to occur in patients with AS.
Objective: This cross-sectional study aimed at determining the differences between the
patients with AS and healthy controls in sleep quality, as well as assessing the relationship
between the sleep quality and disease activity.
Method: In order to assess sleep quality, ﬁfty-ﬁve patients with AS (40 men, 15 women; mean
age,  43 ± 1 years) who fulﬁlled the modiﬁed New York criteria and ﬁfty-ﬁve comparable
controls (40 men, 15 women; mean age, 42 ± 9 years) completed the Pittsburgh Sleep Qual-
ity  Index (PSQI) questionnaire. The disease activity was assessed by the Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI).
Results: Ankylosing spondylitis was associated with a signiﬁcantly impaired sleep quality
according to the total PSQI scores (p = 0.001). Signiﬁcant differences were found between
the patients with AS and healthy controls in PSQI domains, including “subjective sleep
quality” (p = 0.010), “sleep duration” (p = 0.011), “habitual sleep efﬁciency” (p = 0.034), “sleep
disturbances” (p = 0.003) and “daytime dysfunction” (p = 0.009) but not in “sleep latency”, “use
of  sleep medication”. There was a signiﬁcant positive correlation between the BASDAI and
PSQI  scores (r = 0.612, p = 0.001).
Conclusion: In the current study, we found that the sleep disturbances were signiﬁcantly
higher in patients with AS in comparison to controls. Patients with active disease had worse
sleep quality. In addition, disease activity was correlated with the scores of most of the PSQIsubscales. Sleep quality assessment should be a tool for evaluating patients with AS.
©  2015 Elsevier Editora Ltda. All rights reserved.∗ Corresponding author.
E-mail: drebulak@yahoo.com (E. Aydin).
http://dx.doi.org/10.1016/j.rbre.2014.12.007
2255-5021/© 2015 Elsevier Editora Ltda. All rights reserved.
r e v b r a s r e u m a t o l . 2 0 1 5;5 5(4):340–345 341




Índice de Qualidade do Sono de
Pittsburgh
Qualidade do sono
r  e  s  u  m  o
Introduc¸ão: A espondilite anquilosante (EA) é uma doenc¸a reumática inﬂamatória crônica
caracterizada pela inﬂamac¸ão da pelve e da coluna vertebral, que resulta em uma restric¸ão
na mobilidade da coluna vertebral. Em decorrência da postura alterada e da dor inﬂamatória
noturna, os distúrbios do sono são passíveis de ocorrer em pacientes com EA.
Objetivo: Determinar as diferenc¸as entre os pacientes com EA e controles saudáveis na
qualidade do sono, bem como avaliar a relac¸ão entre a qualidade do sono e a atividade da
doenc¸a.
Método: Para avaliar a qualidade do sono, 55 pacientes com EA (40 homens, 15 mulheres,
idade média 43 ± 1 anos) que preencheram os critérios modiﬁcados de Nova York e 55
controles comparáveis (40 homens, 15 mulheres, idade média 42 ± 9 anos) preencheram
o  questionário Índice de Qualidade do Sono de Pittsburgh (PSQI). A atividade da doenc¸a foi
avaliada pelo Bath Ankylosing Spondylitis Disease Activity Index (BASDAI).
Resultados: A espondilite anquilosante se correlacionou signiﬁcativamente com a qualidade
de  sono prejudicada de acordo com os escores totais do PSQI (p = 0,001). Foram encontradas
diferenc¸as  signiﬁcativas entre os pacientes com EA e controles saudáveis nos domínios
do  PSQI, incluindo “qualidade subjetiva do sono” (p = 0,010), “durac¸ão do sono” (p = 0,011),
“eﬁciência do sono habitual” (p = 0,034), “distúrbios do sono” (p = 0,003) e “disfunc¸ão diurna”
(p  = 0,009), mas não na “latência do sono” e no “uso de medicac¸ão para dormir”. Houve uma
correlac¸ão  positiva entre as pontuac¸ões do BASDAI e do PSQI (r = 0,612, p = 0,001).
Conclusão: Veriﬁcou-se que os distúrbios do sono foram signiﬁcativamente maiores em
pacientes com EA em comparac¸ão com os controles. Os pacientes com doenc¸a ativa apre-
sentaram pior qualidade de sono. Além disso, a atividade da doenc¸a esteve correlacionada
com a pontuac¸ão da maior parte das subescalas do PSQI. A investigac¸ão da qualidade do
sono deve ser uma ferramenta usada na avaliac¸ão de pacientes com EA.

























nkylosing spondylitis (AS) is a chronic, inﬂammatory
heumatic disease characterized by the inﬂammation of the
elvis and spine, that results in a restriction in the mobil-
ty of the spine. The prevalence of sleep disorders in AS
atients varies in a range of 54% to 64%, according to the
ecent articles.1–3 AS patients report problems with their sleep
ncluding difﬁculty in initiating sleep, nighttime pain, morn-
ng stiffness and poor sleep quality.4 Consequently, sleeping
roblem has a negative impact on daily life by increas-
ng fatigue, pain and impairing psychological health on the
ffected patients.2,5,6
Altered sleep quality seems to be multi-factorial in patients
ith AS. Pro-inﬂammatory cytokines, such as TNF- and IL-1,
re known to interfere with the physiological sleep pattern.7–9
urthermore, inﬂammatory pain which is the characteristic
f the disease, is typically worse at nighttime and affects the
uality of sleep. In addition, spinal deformities that emerge
ith the progression of the disease interfere with ﬁnding a
omfortable sleep position. Another possible explanation for
leep disturbances might be increased pain, depression and
atique in patients with AS.1,10 These are common complaints
hat can inﬂuence sleep and vice versa. Restricted respiratory
unctions are also common in AS and might have an additional
egative impact on the sleep quality.11There has been an increasing understanding of the impor-
tance of sleep disturbances in patients with rheumatic
diseases.1,12–15 As for AS, more  than half of the patients
report sleep disturbances. From the point of patients’ qual-
ity of life, it is necessary to understand the disrupted
components of sleep and their relationship with disease
ﬂares.
In addition, sleep problems were suggested to be of
higher priority for the improvement of the patients with AS
than the patients with other rheumatoid diseases.16 How-
ever, there is not any speciﬁc questionnaire being used
as an assessment tool. Understanding the affected com-
ponents of sleep in AS would help us to develop new
instruments.
There are a few documented data about sleeping problems
in AS. These data are mostly from the prevalence studies in
which the sleep quality assessment was not a primary end-
point. Moreover, there is a lack of evidence concerning any
difference between AS patients and healthy people in terms
of sleep quality.
The objective of this study was to evaluate the effects of
AS on sleep quality. The following questions were speciﬁcally
addressed: (1) Is there any difference between AS patients
and healthy individuals in terms of sleep quality? (2) If
so, which components of sleep are affected in AS? (3) Is
there any relationship between disease activity and sleep
disturbances?
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Table 1 – Demographic characteristics of patients with
ankylosing spondylitis.
n (%)
Disease duration (years) 15 ± 9.8
Family history 10 (18.9%)
Sleeping partner 43 (81.1%)
Regular exercise habit 14 (26.4%)
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Methods
This study protocol was in a cross-sectional design. Fifty-ﬁve
patients, who  met  the Modiﬁed New York Criteria for AS and
ﬁfty-ﬁve healthy subjects were included in the study. Exclu-
sion criterion was any co-existing disease or medication that
may interfere with sleep. Demographic data, disease duration,
treatment regimens, smoking status and exercise habit were
documented for each patient. The presence of spinal kyphosis
on visual inspection and serum C-reactive protein (CRP) levels
were also recorded.
Sleep  disturbance
All subjects completed the Pittsburgh Sleep Quality Index
(PSQI) questionnaire for the assessment of sleep quality. PSQI
is a self-report questionnaire that evaluates sleep quality over
one month.17 It consists of nineteen questions which ﬁnally
generate seven component scores: “subjective sleep quality”,
“sleep latency”, “sleep duration”, “habitual sleep efﬁciency”,
“sleep disturbances”, “use of sleep medication” and “daytime
dysfunction”. These nineteen items are used for scoring. A
total score above 5 is associated with a poor sleep quality. In
various diseases, the PSQI has been used as an assessment
tool to detect sleep disturbances.18
Disease  activity
The level of disease activity was determined in each patient
using the Bath Ankylosing Spondylitis Disease Activity Index
(BASDAI). BASDAI is a self-rated questionnaire that consists of
6 questions (Q) pertaining to the ﬁve major symptoms of AS:
fatigue (Q1); spinal pain (Q2); joint pain/swelling (Q3); enthesi-
tis (Q4); the duration of morning stiffness (Q5) and the severity
of morning stiffness (Q5).19,20
Functional  status
Bath Ankylosing Spondylitis Functional Index (BASFI) was
used to determine functional status. The BASFI is a self-
administered inventory consisting of 10 questions. The ﬁrst 8
questions assess the functional limitations related to anatom-
ical limitations and the last 2 questions analyze the patients’
ability to perform daily tasks.21,22
Statistical  analysis
The Kolmogorov–Smirnov test was used to assess the nor-
mality of numeric variables. The independent sample t
test was used to compare normally distributed numeri-
cal variables between two groups and the results were
expressed as mean ± standard deviation. The comparison
of the scores and numerical variables that were non-
normally distributed between two groups was made by the
Mann–Whitney U-test and the results were expressed as
median (25–75 percentiles). The chi-square test was used for
nominal variables. The Spearman test was used for correla-
tion analysis. Values of p < 0.05 were considered statistically
signiﬁcant.NSAI˙D, non-steroidal anti-inﬂammatory drug; DMARD, disease
modifying drug; TNF-,  tumor necrosis factor-.
Results
The basic characteristics of patients who enrolled in the study
are shown in Table 1. There was not any signiﬁcant differ-
ence between the patient and control groups (43 ± 10 years
vs 42 ± 9 years, p = 0.604) in age. There were 40 male and 15
female participants in each group (p = 1.000).
Ankylosing spondylitis was associated with a signiﬁ-
cantly impaired sleep quality according to the total PSQI
scores (p = 0.001). There were signiﬁcant differences between
the patients with AS and healthy controls in “subjective
sleep quality” (p = 0.010), “sleep duration” (p = 0.011), “habit-
ual sleep efﬁciency” (p = 0.034), “sleep disturbances” (p = 0.003)
and “daytime dysfunction” (p = 0.009) subscale scores but
not in the “sleep latency”, “use of sleep medication” scores
(Table 2). Signiﬁcant positive correlations were found between
BASDAI scores and the “subjective sleep quality” (r = 0.475,
p < 0.001), “sleep latency” (r = 0.419, p = 0.002), “sleep dura-
tion” (r = 0.354, p = 0.009), “habitual sleep efﬁciency” (r = 0.444,
p = 0.001), “sleep disturbances” (r = 0.426, p = 0.001), “daytime
dysfunction” (r = 0.445, p = 0.001) and the total PSQI scores
(r = 0.612, p < 0.001) of AS patients (Fig. 1). In addition, BASDAI
scores that suggested active disease (≥4) were signiﬁcantly
associated with higher PSQI scores (p < 0.001). The median
PSQI score was 4 (3–6) in patients with inactive disease and 8
(6.8–12) in patients with active disease. The detailed analysis
of each BASDAI question revealed that all questions corre-
lated with PSQI scores (r = 0.453, p = 0.001 for Q1; r = 0.516,
p < 0.001 for Q2; r = 0.431, p = 0.001 for Q3; r = 0.378, p = 0.005 for
Q4; r = 0.457, p = 0.001 for Q5 and r = 0.442, p = 0.001 for Q6). In
addition, serum CRP levels of AS patients (n = 43) correlated
with the sleep duration (r = 0.367, p = 0.014) and total Pittsburgh
scores (r = 0.333, p = 0.029).
There was a signiﬁcant correlation between the level of
fatigue measured using the ﬁrst item of BASDAI and the
“subjective sleep quality” (r = 0.275, p = 0.044), “sleep duration”
(r = 0.404, p = 0.002), “sleep disturbances” (r = 0.276, p = 0.043),
“daytime dysfunction” (r = 0.400, p = 0.003), and total Pittsburgh
scores (r = 0.453, p = 0.001).A signiﬁcant correlation was found between the functional
status of the patients (n = 44) and the “subjective sleep qual-
ity” (r = 0.367, p = 0.014), “habitual sleep efﬁciency” (r = 0.360,
r e v b r a s r e u m a t o l . 2 0 1 5;5 5(4):340–345 343
Table 2 – Comparison of two groups in regards of Pittsbugh Sleep Quality Index (PSQI) scores.
Ankylosing
spondylitis (n = 55)
Control
(n  = 55)
p
Age (years) 43  ± 10 42 ± 9 0.604
Gender (male/female) 40/15 40/15 1.000
Subjective Sleep Quality 1 (1–2)a 1 (0–1)a 0.010
Sleep Latency 1 (0–2)a 1 (0–2)a 0.181
Sleep Duration 1 (0–1)a 0 (0–1)a 0.011
Habitual Sleep Efﬁciency 0 (0–2)a 0 (0–0)a 0.034
Sleep Disturbances 2 (1–2)a 1 (1–2)a 0.003
Use of Sleep Medication 0 (0–0)a 0 (0–0)a 0.096
Daytime Dysfunction 1 (0–2)a 0 (0–1)a 0.009


















sp values show the difference between ankylosing spondylitis and con
a Data are presented as median (25–75 percentiles).
 = 0.017), “sleep disturbances” (r = 0.494, p = 0.001), “daytime
ysfunction” (r = 0.376, p = 0.012), and total Pittsburgh scores
r = 0.483, p = 0.001).
There was no statistically signiﬁcant correlation between
he sleep quality and age, gender, disease duration, exercise
abit, smoking behavior of the patients or spinal kyphosis
p > 0.05). There was no signiﬁcant relationship between the
rugs used and sleep disturbances.
iscussion
n this cross-sectional controlled study, our ﬁndings suggest
hat patients with AS were signiﬁcantly more  affected by sleep
isturbances than the healthy individuals. In addition, there
as a signiﬁcant relationship between the sleep problem and
isease activity and inﬂammatory state. The total PSQI scores
ncreased with increasing scores of BASDAI and serum CRP

















ig. 1 – Correlation of total BASDAI scores with total PSQI
cores.roups.
The ﬁrst question addressed in this study was whether
the patients with AS had a worse sleep quality than healthy
people. In our study, the median value of PSQI scores was
greater in AS patients than that of the healthy subjects (7
and 5, respectively). Since a total score above 5 is associated
with poor sleep quality, we concluded that patients with AS
has poor sleep quality. Similar to our study, a previous study
involving 62 AS patients also indicated a poor sleep quality in
AS patients, since the mean score of PSQI was found as 5.8.3
In another study involving 11 subjects with AS and 11 healthy
volunteers, the sleep pattern was found worse in AS patients.6
In our study, the incidence of poor sleep quality among the
AS patients was found as 58.1%. The incidence of altered sleep
pattern among the individuals with AS, has been reported
as 64.5% by Hakkou et al., 54% by Ward et al. and 54.8% by
Günaydın et al.1–3 Similarly, Da Costa et al. found the incidence
of sleep problems as 69% in patients with spondyloarthritis.13
Consistently with the current literature, our results empha-
size that a poor sleep quality might be expected in more  than
half of the patients with AS.
The second question addressed in this study was which
components of sleep quality have been affected in AS. PSQI
assesses seven components of sleep. In patients with AS,
ﬁve of these components were found to be signiﬁcantly
worse compared to normal individuals. The “Subjective sleep
quality”, “sleep duration”, “sleeps disturbances”, “habitual
sleep efﬁciency” and “daytime dysfunction” were signiﬁcantly
impaired. In addition, all PSQI components, except “sleep
medication” were found to be correlated with disease activ-
ity. Possible explanations for the reduced sleep duration and
increased sleep disturbances might be the nocturnal increases
in the inﬂammation, pain and stiffness. In a recent survey,
people with rheumatic diseases reported a sleep duration less
than 6 h per night.23 Although there are considerable indi-
vidual differences in sleep duration, healthy adults sleep an
average of 7–8 h per day.24 Insufﬁcient sleep, nighttime awak-
enings and loss of sleep efﬁciency enhance depression, fatigue
and life satisfaction in these patients.2,5,10 In a longitudinal
survey including 175 subjects with AS, 54% of the patients
deﬁned poor sleep quality as the most important quality of
life concern.2 In another survey involving 295 AS patients,
41% of the subjects complaining of fatigue were experienc-
ing more  than three episodes of awakening every night. In
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the light of foregoing data, daytime dysfunction detected by
our study should not be surprising. As the symptoms of AS
usually appear in early adulthood, daytime dysfunction due
to sleep problems may have socioeconomic consequences for
individual patients and for society.
In respect of sleep latency, there was no signiﬁcant differ-
ence between the groups, whereas the disease activity scores
correlated with sleep latency. According to a previous study,
pain in AS was found to be correlated with the difﬁculty in
getting to sleep.6 In view of our ﬁndings, the preserved sleep
latency in AS patients might be explained by the character
of inﬂammatory pain that worsen after middle of the night.
According to our data, we concluded that the main problem
was due to maintaining sleep, not initiating it.
Third question addressed in this study was whether there
was a relationship between the disease-speciﬁc variables and
sleep quality. It is a clinically relevant question because the
proper management of the disease could improve sleep qual-
ity and health-related quality of life. We found a positive
correlation between the disease activity and sleep distur-
bances. According to their BASDAI scores and CRP levels,
the patients with active disease had worse sleep quality. In
detailed analysis, each question of BASDAI reﬂecting fatique,
spinal pain, joint pain/swelling, enthesitis, the duration and
severity of morning stiffness revealed a positive correlation
with the PSQI scores.
Although pain and stiffness are the major symptoms
of the disease, more  than half of the AS patients report
fatigue.5,25 The relationship between fatigue and sleep qual-
ity in AS patients was reported previously.3,26,27 Similarly, in
the present study, patients reporting high levels of fatigue had
higher PSQI scores as well. Improving sleep quality may help
to decrease fatigue and pain, which in turn may improve the
functionality and overall quality of life. Our results indicated
that the patients with higher BASFI scores had worse sleep
quality according to PSQI. Sleep was assessed by the fourth
item of the Hamilton Anxiety Rating Scale in a previous study
and similarly to our results, it was reported that the pain inten-
sity, disease activity and functional status had impacts on the
sleep quality.1
The results of this study also suggest that the evaluation
of the sleep quality should be a part of outcome assess-
ment in AS. In a study of 2138 subjects with inﬂammatory
arthropathies, patients were asked to rank health prob-
lems, including pain, morning stiffness, physical functioning,
fatigue, sleep, social function and emotional well-being. The
rate of the patients who described priority for the improve-
ment in sleep problems was signiﬁcantly higher among
AS patients in comparison to the other rheumatic disorder
groups.16 These data emphasize the importance of the assess-
ment of sleep problems in AS. Ankylosing Spondylitis Quality
of Life (ASQOL) questionnaire has a general question about
sleep, but this is a yes/no question and insufﬁcient to under-
stand the real impact.28 By the way, we can conclude that the
instruments that assess the impact of AS on sleep quality and
its inﬂuence to daily life are generally lacking.Certainly, our study has some limitations. The sample size
was small and the study design was cross-sectional. There-
fore, the results of this study need a conﬁrmation by a study
in a longitudinal observational design with a larger sample 0 1 5;5 5(4):340–345
size. In addition, we  did not assess the anatomical impair-
ments objectively, in order to ﬁnd out their relationship with
sleep quality. A physical examination consisting of thoracic
expansion and Bath Ankylosing Spondylitis Metrology Index,
could give valuable data.29 However, in this context, we  tried
to deﬁne a relationship between spinal kyphosis, disease
duration and PSQI scores, but there was no signiﬁcant rela-
tionship. Moreover, smoking behavior was asked only to the
patient group. It was a yes/no question which was not ask-
ing the amount of consumption and former addiction. Further
researches concerning the effect of smoking habit on sleep,
should be conducted. Finally, we  did not use any tool to assess
neither the quality of life nor mental health status.
Future studies could be designed to ﬁnd out how sleep
problems interact daily life, such as quality of life or mental
health status in patients with AS. Evaluation of spinal mobil-
ity and radiological changes by means of Bath Ankylosing
Spondylitis Metrology Index and Bath Ankylosing Spondylitis
Radiology Index as well as the analysis of real inﬂamma-
tory state, by using magnetic resonance imaging should be
included in these studies.29,30 Long term studies investigating
how different therapy regimens impact sleep quality and the
polysomnography studies could provide valuable data.
Conclusion
In the current study, we  found that sleep disturbances were
signiﬁcantly higher in patients with AS. Patients with active
disease had worse sleep quality. In addition, disease activity
was correlated with most of the PSQI subscale scores. It seems
that the disease activity has a greater impact on sleep quality
than the anatomical impairments. Proper management of the
disease can improve sleep quality and health related quality
of life. Furthermore, the assessment of sleep quality should be
used routinely in patients with AS.
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